Sarcoma
Welcome,         Profile    Billing    Logout  
 506 Companies   302 Products   302 Products   167 Mechanisms of Action   1360 Trials   122555 News 


«12...1617181920212223242526...15261527»
  • ||||||||||  Journal:  Expanding the Spectrum of NR4A3 Fusion-Positive Gynecologic Leiomyosarcomas. (Pubmed Central) -  May 17, 2024   
    All cases showed high NR4A3 RNA expression levels and NOR1 (NR4A3) nuclear staining similar to salivary gland acinic cell carcinoma and a subset of extraskeletal myxoid chondrosarcomas harboring NR4A3 rearrangement. NOR1 (NR4A3) immunohistochemistry may serve as a useful diagnostic marker of NR4A3 fusion-positive gynecologic leiomyosarcomas.
  • ||||||||||  Journal:  CHRNA6 RNA in situ hybridization is a useful tool for the diagnosis of extraskeletal myxoid chondrosarcoma. (Pubmed Central) -  May 17, 2024   
    All examined cases of histological mimics were negative for CHRNA6 overexpression; however, limited CHRNA6 expression, not reaching a threshold of greater than 5 puncta or one aggregate of chromogen in more than 25% of cells, was observed in 69 of 685 mimics (10.1%), spanning an array of mesenchymal tumors. Taken together, these findings suggest that, with careful interpretation and the use of appropriate thresholds, CHRNA6 RNA CISH is a potentially useful ancillary histological tool for the diagnosis of EMC.
  • ||||||||||  Journal:  Recurrent Wnt Pathway and ARID1A Alterations in Sinonasal Olfactory Carcinoma. (Pubmed Central) -  May 17, 2024   
    A small subset of neuroepithelial tumors might better fit into the superseding molecular category of IDH2-mutant sinonasal carcinoma. At this point, sinonasal neuroendocrine and neuroepithelial tumors may best be regarded as a histologic and molecular spectrum that includes core groups of ONB, olfactory carcinoma, neuroendocrine carcinoma, and IDH2-mutant sinonasal carcinoma.
  • ||||||||||  Review, Journal:  Risk of Subsequent Neoplasms in Childhood Cancer Survivors After Radiation Therapy: A Comprehensive PENTEC Review. (Pubmed Central) -  May 17, 2024   
    Given the linear dose response, improved conformality around the target volume that limits the high dose volume might be a promising strategy for reducing the risk of SNs after RT. Other host- and treatment-related factors such as age and chemotherapy play a significant contributory role in the development of SNs and should be considered when estimating the risk of SNs after RT among childhood cancer survivors.
  • ||||||||||  ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Intraosseous Rhabdomyosarcoma of the Head and Neck: A Case Report and Review of the Literature (Mezzanine level of the exhibition area) -  May 17, 2024 - Abstract #BAHNO2024BAHNO_84;    
    The potential therapeutic benefit of their association with ALK overexpression has been highlighted in few studies. Increased awareness of this entity and the challenges surrounding diagnosis, management, and quality of life is important, in order to improve survival outcomes for patients presenting with this tumour.
  • ||||||||||  Review, Journal:  Understanding exosomes: Part 2-Emerging leaders in regenerative medicine. (Pubmed Central) -  May 17, 2024   
    Today exosomes have been applied in numerous contexts including neurodegenerative disorders (Alzheimer's disease, central nervous system, depression, multiple sclerosis, Parkinson's disease, post-traumatic stress disorders, traumatic brain injury, peripheral nerve injury), damaged organs (heart, kidney, liver, stroke, myocardial infarctions, myocardial infarctions, ovaries), degenerative processes (atherosclerosis, diabetes, hematology disorders, musculoskeletal degeneration, osteoradionecrosis, respiratory disease), infectious diseases (COVID-19, hepatitis), regenerative procedures (antiaging, bone regeneration, cartilage/joint regeneration, osteoarthritis, cutaneous wounds, dental regeneration, dermatology/skin regeneration, erectile dysfunction, hair regrowth, intervertebral disc repair, spinal cord injury, vascular regeneration), and cancer therapy (breast, colorectal, gastric cancer and osteosarcomas), immune function (allergy, autoimmune disorders, immune regulation, inflammatory diseases, lupus, rheumatoid arthritis). This scoping review is a first of its kind aimed at summarizing the extensive regenerative potential of exosomes over a broad range of diseases and disorders.
  • ||||||||||  Journal:  Hemangiosarcoma Cells Promote Conserved Host-Derived Hematopoietic Expansion. (Pubmed Central) -  May 17, 2024   
    Furthermore, gene expression profiling data revealed hemangiosarcoma cells expressed a repertoire of hematopoietic cytokines capable of regulating the surrounding stromal cells. We conclude that canine hemangiosarcomas, and possibly human angiosarcomas, maintain molecular properties that provide hematopoietic support and facilitate stromal reactions, suggesting their potential involvement in promoting the growth of hematopoietic tumors.
  • ||||||||||  imatinib / Generic mfg.
    Journal, Stroma:  A Unique Case of Mesenteric Gastrointestinal Stromal Tumor Presenting as an Acute Abdomen. (Pubmed Central) -  May 17, 2024   
    The tumor was resected, and the genomic test results confirmed the KIT (exon 11) mutation. Although the tumor had a low mitotic rate, the tumor was large enough to warrant the initiation of adjuvant imatinib mesylate for 36 months with regular bloodwork and imaging.
  • ||||||||||  Preclinical, Journal:  Osteosarcoma with widespread metastasis in a 1-year-old crossbred rabbit. (Pubmed Central) -  May 17, 2024   
    Innumerable metastatic osseous masses were present throughout the body, including cerebral, pulmonary, hepatic, subcutaneous, and skeletal muscular metastases. Postmortem findings confirmed widespread, metastatic osteosarcoma, with the primary lesion within the left maxilla.
  • ||||||||||  Review, Journal, FDG PET:  Molecular Imaging in Soft-tissue Sarcoma: Evolving Role of FDG PET. (Pubmed Central) -  May 16, 2024   
    This article reviews the evolving role of FDG PET in initial diagnosis, staging, treatment response assessment, and restaging. Further studies on the use of FDG PET in soft sarcoma are needed, particularly for rare histopathologic subtypes.
  • ||||||||||  Review, Journal:  PET/CT and PET/MR in Soft Tissue Sarcoma: An Update. (Pubmed Central) -  May 16, 2024   
    In this article, we will primarily focus on the staging, risk stratification, imaging recommendations, and interpretations in accordance with the Children's Oncology Group trials. We will review the results and recommendations of International Soft Tissue Sarcoma Database Consortium and European trials in relevant sections where they provide complementary guidelines.
  • ||||||||||  Journal:  Biologically significant interaction of human herpesvirus 8 viral interferon regulatory factor 4 with ubiquitin-specific protease 7. (Pubmed Central) -  May 16, 2024   
    The present study identifies the interaction as important for HHV-8 productive replication and, indeed, for vIRF-4 expression and reveals a new function of vIRF-4 via inhibition of the activity of TRAF3, a pivotal mediator of host-cell antiviral activity through activation of cellular IRFs and induction of type-I interferons. These findings identify potential targets for the development of novel anti-HHV-8 agents, such as those able to disrupt vIRF-4-USP7 interaction or vIRF-4-stabilizing USP7 activity.
  • ||||||||||  5-fluorouracil / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Journal:  Unveiling the anticancer potential of the ethanolic extract from Trichoderma asperelloides. (Pubmed Central) -  May 16, 2024   
    A synergistic effect between ExtTa and doxorubicin was found in the treatment of osteosarcoma Saos-2 cells, as well as with 5-fluorouracil in the treatment of HCT116 colorectal carcinoma cells using CompuSyn software. Our data unravel the presence of bioactive compounds with cytotoxic effects against cancer cells present in T. asperelloides ethanolic crude extract, with the potential for developing novel anticancer agents.
  • ||||||||||  Review, Journal:  Diagnosis and Management of Desmoid Fibromatosis of the Breast. (Pubmed Central) -  May 16, 2024   
    Current treatment guidelines for desmoid tumors do not focus on the breast as a site of disease and are purposefully ambiguous due to the paucity of evidence available. We aim to review the literature concerning desmoid fibromatosis of the breast and propose an algorithm for current evidence-based management of this rare disease in the context of our experience with this pathology at a high-volume quaternary referral center.
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
    Journal:  Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors. (Pubmed Central) -  May 16, 2024   
    Notably, pyrotinib plus trastuzumab was more effective than trastuzumab plus pertuzumab in inhibiting tumor growth and HER2 downstream pathways in HER2+ breast cancer with primary resistance to trastuzumab. These findings support clinical testing of the therapeutic efficacy of dual anti-HER2 treatment combining an intracellular small molecule with an extracellular antibody.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) -  May 16, 2024   
    P2,  N=52, Active, not recruiting, 
    Our findings implicate aberrant ERV-mediated SP140 expression as a novel mechanism contributing to immune gene dysregulation in a wide range of cancer cells. Trial primary completion date: Mar 2024 --> Mar 2025 | Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Mar 2025
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
    Trial completion date, Trial primary completion date:  A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas (clinicaltrials.gov) -  May 16, 2024   
    P2,  N=57, Active, not recruiting, 
    Stable, newly developed [99mTc]DTPA-FLUT seeks its way to internalize into RMS cancer cells, indicating it could be a potential candidate for the diagnosis of RMS cancer. Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
  • ||||||||||  Trial completion, Trial primary completion date:  MYLUNAR: MYometrial Lesion UltrasouNd And mRi (clinicaltrials.gov) -  May 16, 2024   
    P=N/A,  N=2353, Completed, 
    Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025 Recruiting --> Completed | Trial primary completion date: Jan 2022 --> Dec 2023